Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy

Al-Nawakil, Chadi; Tamburini, Jérôme; Bardet, Valérie; Chapuis, Nicolas; Bourry, Edward; Roux, Christian; Park, Sophie; Choquet, Sylvain; Dreyfus, F.; Bouscary, Didier

doi:10.1080/10428190802290660

Cited by 22 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bortezomib is a proteasome inhibitor successfully used for the therapy of multiple myeloma even in patients with extraosseous disease, now experimented in primary and secondary PCL. In this regard, the information are still limited [14][15][16][17], but recently Musto et al [17] described 12 PCL (8 primary and 4 secondary) treated with bortezomib-containing regimen, obtaining promising results, with an overall response rate of 92% (5 PR, 4 VGPR, 2 CR), and a median survival of 8 months. Despite the use of bortezomib, in our case, the disease rapidly spread, with the involvement of unusual sites.…”

Section: Discussionmentioning

confidence: 95%

Primary plasma cell leukemia followed by testicular plasmacytoma

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 95%

Primary plasma cell leukemia followed by testicular plasmacytoma

et al. 2011

View full text Add to dashboard Cite

show abstract

“…The median OS was 12 months (Table 4). Al-Nawakil et al [95] recently reported four case reports of patients with PCL treated with the bortezomib, adriamycin and dexamethasone combination (PAD), three of whom achieved VGPR and one a CR. These data altogether represents evidence to suggest bortezomib and combinations schemes to be highly active as induction therapy in PCL.…”

Section: Bortezomibmentioning

confidence: 98%

Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis

Jiménez-Zepeda

Dominguez-Martinez

2009

Int J Hematol

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is an aggressive variant of multiple myeloma and is characterized by the presence of >20% and/or an absolute number of greater 2 x 10(9)/L plasma cells circulating in the peripheral blood. PCL represents approximately 2-4% of all MM diagnosis and exists in two forms: primary PCL (PPCL, 60% of cases) presents de novo, whereas secondary PCL (SPCL, accounts for the remaining 40%) consists of a leukemic transformation in patients with a previously diagnosed MM. Because the mechanisms contributing to the pathogenesis of PCL are not fully understood, immunophenotyping, genetic evaluation (conventional karyotype, FISH, GEP and array-CGH), and immunohistochemistry are really important tools to investigate why plasma cells escape from bone marrow and become highly aggressive. Since treatment with standard agents and steroids is poorly effective, a combination of new drugs as part of the induction regimens and bone marrow transplant (autologous and allogeneic approaches) could nearly overcome the poor prognosis exhibited by PCL patients.

show abstract

“…The efficacy of the combination of bortezomib with dexamethasone and melphalan 85 or doxorubicin 82,86 has also been reported in selected smaller case reports and series. Bortezomib and dexamethasone has been shown to be useful in three patients with primary PCL, t(4;14) and CD27 expression 87 .…”

Section: Therapeutic Optionsmentioning

confidence: 98%

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

et al. 2012

View full text Add to dashboard Cite

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary PCL in patients with relapsed/refractory myeloma. Primary PCL is a distinct clinic-pathologic entity with different cytogenetic and molecular findings. The clinical course is aggressive with short remissions and survival duration. The diagnosis is based upon the percentage (≥ 20%) and absolute number (≥ 2 × 10 9/L) of plasma cells in the peripheral blood. It is proposed that the thresholds for diagnosis be reexamined and consensus recommendations are made for diagnosis, as well as, response and progression criteria. Induction therapy needs to begin promptly and have high clinical activity leading to rapid disease control in an effort to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens are recommended followed by high-dose therapy with autologous stem-cell transplantation (HDT/ASCT) if feasible. Allogeneic transplantation can be considered in younger patients. Prospective multicenter studies are required to provide revised definitions and better understanding of the pathogenesis of PCL.

show abstract

Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy

Cited by 22 publications

References 13 publications

Primary plasma cell leukemia followed by testicular plasmacytoma

Primary plasma cell leukemia followed by testicular plasmacytoma

Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Contact Info

Product

Resources

About